679. Geographical analysis of Antimicrobial Consumption Surveillance using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB JAPAN) 2011-2013
Session: Poster Abstract Session: Stewardship: Data and Program Planning
Thursday, October 5, 2017
Room: Poster Hall CD
  • IDweek2017tanabe.pdf (180.4 kB)
  • Background: Although monitoring antimicrobial use (AMU) in medical institutions is important for countermeasures against antimicrobial resistance (AMR), there has been little data regarding AMU in Japan based on the prefecture unit. Accordingly, our objective was to assess whether AMU monitoring through the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), which archives the e-claim data, could be useful.

    Methods: The quantities and patterns of oral and parenteral AMU from 2011 to 2013 in Japanese medical institutions in 47-prefecture units were analyzed using NDB collected through the Ministry of Health, Labor and Welfare of Japan, which accounted for 98% of total claim data in Japan. The data were analyzed in accordance with the Anatomical Therapeutic Chemical (ATC) classification using the defined daily dose (DDD) as a measurement unit, as recommended by the WHO Collaborating Centre for Drug Statistics Methodology. The AMU data was normalized and reported as DDDs per 1000 inhabitants in each prefecture per day (DID). Trends of DID from 2011 to 2013 in each prefecture was analyzed and inter-regional comparison was performed.

    Results: All prefectures demonstrated increased trends in both oral and parenteral AMU (DID) from 2011 to 2013. The median (max, min) AMU (DID) for oral and parenteral AMUs in 2011, 2012, 2013 were 12.7 (15.3, 10.1), 13.2 (15.9, 10.8), 13.2(15.9, 10.9), and 0.84 (1.04, 0.54), 0.89 (1.05, 0.57), 0.92 (1.11, 0.62), respectively. When the data was analyzed based on dividing Japan into three regions (eastern, central, and western Japan), there were significant geographical difference in both oral and parenteral AMU, with the highest values in the western Japan.

    Conclusion: AMU has increased from 2011 and 2013 regardless of the dosage form in all prefectures in Japan. Geographical analysis demonstrated regional distribution of AMU within the country. The NDB can be used as a tool for AMU monitoring to assess regional action to combat against AMR.

    Masaki Tanabe, MD, PhD1, Yuichi Muraki, PhD2, Daisuke Yamasaki, PhD1, Genta Kato, MD, PhD3 and Tetsuya Yagi, M.D., Ph.D.4, (1)Department of Infection Control and Prevention, Mie University Hospital, Mie, Japan, (2)Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto, Japan, (3)Solutions Center for Health Insurance Claims, Kyoto University, Kyoto, Japan, (4)Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Aichi, Japan


    M. Tanabe, None

    Y. Muraki, None

    D. Yamasaki, None

    G. Kato, None

    T. Yagi, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.